Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10052504 | 0.77 | SLC6A4 (0.53) | SLC6A4SLC6A3SLC6A2SMN1; SMN2MAPT | |
| SCHEMBL13543971 | 0.75 | CCR5 (0.41) | SMN1; SMN2MAPTMEN1KMT2ATSHR | |
| SCHEMBL14944336 | 0.70 | HDAC4 (0.43) | SLC6A4SLC6A3RXRARXRBRXRG | |
| SCHEMBL10052514 | 0.68 | SLC6A3 (0.47) | SLC6A4SLC6A3SLC6A2NPC1RAB9A | |
| SCHEMBL13253927 | 0.66 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL20876280 | 0.64 | SLC6A4 (0.45) | SLC6A4SLC6A3OPRM1SLC6A2 | |
| SCHEMBL10052501 | 0.64 | OPRM1 (0.57) | SLC6A4SLC6A3OPRM1SLC6A2 | |
| SCHEMBL20500670 | 0.64 | SLC6A4 (0.44) | SLC6A4SLC6A3SMN1; SMN2MAPTMEN1 | |
| SCHEMBL5153993 | 0.64 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14893938 | 0.63 | OPRM1 (0.57) | SLC6A4SLC6A3OPRM1SLC6A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505716-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505716-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160115123-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160115123-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2016-04-28 | — | — | US | disclosed |
| EP-2974724-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | Sunovion Pharmaceuticals Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9056830-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056830-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-8754117-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754117-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140073682-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073682-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130137744-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICAL INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137744-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICAL INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8389559-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389559-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120022125-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022125-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| WO-2010091268-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022125-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC6A3 | SLC6A4 4/4885SLC6A3 3/4885RARB 4043/4885 |
| US-20140073682-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC6A3 | SLC6A4 4/4885SLC6A3 3/4885RARB 4043/4885 |
| US-20160115123-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC6A3 | SLC6A4 4/4885SLC6A3 3/4885RARB 4043/4885 |
| US-20130137744-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC6A3 | SLC6A4 4/4885SLC6A3 3/4885RARB 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.